Research, VIEWS AND ANALYSIS

Pharma R&D Annual Review 2023

April 20, 2023

Pharma R&D Annual
Welcome to Pharmaprojects’ 2023 review of trends in pharmaceutical R&D. For over 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article, I’llexamine the state of play at the start of 2023.

Spotlight

National Institute of Molecular Genetics

The Istituto Nazionale di Genetica Molecolare (INGM) is a no-profit research foundation aimed at the discovery and initial development of new therapies and new diagnostics in the fields of tumors and autoimmune diseases. INGM comes to life to be a “translational” medical Research Institute that creates scientific knowledge capable of generating value on the basis of the intellectual property that ensues from its research activities. To achieve these objectives, INGM will develop scientific research strongly connected with clinics, drawing benefit from being located inside one of the most important European hospitals, the IRCCS Ospedale Maggiore of Milan. Research activities are coordinated by a Chief Scientific Officier with scientific and managerial expertise who is supported by a Scientific Advisory Board composed by researchers having a high international profile.

OTHER WHITEPAPERS
news image

Coronavirus (COVID-19) and Its Effect on Pharmaceutical Marketing and Sales

whitePaper | March 16, 2020

With the rapid onset of coronavirus in the United States, many pharma companies are being forced to prepare for a scenario in which their reps cannot visit providers and patients are limited in their ability to visit their healthcare professionals (HCP). The CDC has gone as far as recommending the use of telemedicine and patient portals as primary channels for HCPs and patients to interact.

Read More
news image

The Annual Clinical Trials Round-up 2021

whitePaper | October 13, 2022

In our previous edition of the Clinical Trials Roundup1, we explored the acute disruptions that the COVID-19 pandemic brought to the clinical trials landscape in 2020.

Read More
news image

Drug Shortages HSGAC Majority Staff Report 2023

whitePaper | March 1, 2023

Shortages of critical medications continue to rise—including drugs used in hospital emergency rooms and to treat cancer, prescription medications, and even common over-the-counter treatments like children’s cold and flu medicine.

Read More
news image

Helping Patients Find and Engage with Clinical Trials

whitePaper | June 16, 2022

With increased scrutiny from regulatory agencies, advocacy groups and the public for clinical trial transparency, sponsors are feeling the pressure to ramp up efforts to make their studies more accessible

Read More
news image

Combatting Future Viral Threats with Vaccine Advances

whitePaper | February 3, 2023

Since the beginning of the COVID-19 pandemic, pharmaceutical organizations have experienced major changes, a prime example of which has been the rising requirement for collaborations on multiple different fronts across the industry.

Read More
news image

Strengthening Engagement and Influence with Key Decision Makers

whitePaper | January 5, 2023

This report follows up on the jointly hosted Pharmaforce and elandas webinar which took place on July, 12, 2016, featuring contributions from participating industry leaders who formed the expert panel, as well as the live contributions of the audience of healthcare sales and marketing professionals.

Read More

Spotlight

National Institute of Molecular Genetics

The Istituto Nazionale di Genetica Molecolare (INGM) is a no-profit research foundation aimed at the discovery and initial development of new therapies and new diagnostics in the fields of tumors and autoimmune diseases. INGM comes to life to be a “translational” medical Research Institute that creates scientific knowledge capable of generating value on the basis of the intellectual property that ensues from its research activities. To achieve these objectives, INGM will develop scientific research strongly connected with clinics, drawing benefit from being located inside one of the most important European hospitals, the IRCCS Ospedale Maggiore of Milan. Research activities are coordinated by a Chief Scientific Officier with scientific and managerial expertise who is supported by a Scientific Advisory Board composed by researchers having a high international profile.

Events